Bioidentical Hormones Benefits and Risks in a Clinical Approach

Find out how bioidentical hormones in a clinical approach can support your journey to improved hormonal balance.

Abstract

In this educational post, I share a practical, evidence-informed roadmap for optimizing estrogen, testosterone, and progesterone in women and men who struggle with anxiety, low drive, sleep disturbance, weight change, hot flashes, chronic pain, and sexual dysfunction. I integrate findings from leading researchers and clinical guidelines with my observations from Health Coach Clinic to explain why these symptoms often reflect deficiencies or dysregulation in sex steroids—and how modern delivery methods (pellets, transdermals, orals, injections, and microdosing) compare in efficacy, safety, and patient experience. I show how I structure baseline laboratory evaluation, interpret FSH in context, tailor estradiol and progesterone strategies across peri- and postmenopause, and preserve fertility in younger men using clomiphene when indicated. I also outline how integrative chiropractic care—manual therapy, movement re-education, autonomic balancing, and metabolic coaching—synergizes with hormone therapy to reduce pain, stabilize sleep, and improve body composition. Throughout, I highlight why smoother pharmacokinetics matter, when to favor transdermal estradiol, how to minimize aromatization and DHT spikes, and why validated symptom scales sharpen decisions and track outcomes over time.

Why Hormone Symptoms Often “Don’t Feel Psychological”

When patients tell me “I feel crazy,” “I can’t sleep,” or “I’ve lost my drive,” I listen for the underlying physiology. Across women and men, I commonly see clusters of:

• Mood and cognition: irritability, anxiety, low motivation, “brain fog,” reduced stress tolerance
• Sleep disruption: difficulty falling or staying asleep, non-restorative sleep
• Sexual health: low desire, erectile or arousal difficulties, vaginal dryness, reduced orgasmic intensity
• Metabolic changes: weight gain or inability to lose weight, increased central adiposity, reduced stamina
• Vasomotor symptoms: hot flashes, daytime flushing, night sweats
• Pain syndromes: widespread aches, myalgias, fibromyalgia-like presentations
• Functional performance: loss of “get up and go,” lower exercise capacity

Physiologically, steroid hormones modulate neurotransmission (GABA, serotonin, dopamine), mitochondrial function, muscle protein synthesis, microvascular perfusion, and thermoregulation. Estradiol improves serotonergic tone and endothelial nitric oxide signaling, while testosterone supports dopaminergic motivation circuits, neuromuscular strength, and modulation of nociception (Maki & Henderson, 2016; Morgentaler et al., 2015; Traish et al., 2011). Deficits can present as emotional volatility, pain amplification, and fatigue that mimic primary psychiatric illness. Psychotropics may help symptoms, but when sex steroids are low or poorly signaled, addressing the endocrine driver improves sleep, pain thresholds, and resilience.

Key physiology to remember

• Estradiol: enhances synaptic plasticity and serotonin availability; improves vasodilation and thermoregulation; supports urogenital tissue trophism and collagen synthesis; reduces bone turnover (Maki & Henderson, 2016; North American Menopause Society [NAMS], 2023).
• Testosterone: increases lean mass, red cell mass, and neuromuscular coordination; modulates reward and drive; acts as a prohormone for DHT and estradiol via 5?-reductase and aromatase (Morgentaler et al., 2015; Traish et al., 2011).

How Integrative Chiropractic Care Amplifies Hormone Therapy

As a chiropractor and family nurse practitioner in functional medicine, I see hormones and the neuromusculoskeletal system as a single conversation between the brain, fascia, vessels, and viscera. In practice, aligning biomechanics and autonomic tone improves the effectiveness of hormone therapy.

• Spinal and extremity adjustments: optimize afferent signaling and autonomic balance, reducing sympathetic overdrive that destabilizes vasomotor control and fragments sleep.
• Myofascial release and mobility: decrease nociceptive input and central sensitization, often exacerbated by low estrogen/testosterone states.
• Vagal toning strategies: diaphragmatic breathing, HRV-guided biofeedback, and thoracic/cervical mobility work support parasympathetic dominance at night.
• Nutrition and metabolic support: insulin-sensitizing nutrition, higher-protein plans, and mitochondrial nutrients (e.g., CoQ10, L-carnitine) reduce inflammation and aromatase activity associated with visceral adiposity.
• Progressive resistance training: improves insulin sensitivity and stimulates endogenous androgen signaling and muscle protein synthesis (Phillips & Winett, 2010).

In my clinics, patients who receive coordinated manual care and movement coaching often need lower hormone doses, report fewer side effects, and experience faster improvements in sleep and pain.

My Baseline Labs and Why They Matter

The effectiveness and safety of sex steroids depend on broader physiological factors. I use a structured lab framework to reduce surprises and personalize care:

Minimum baseline

• CBC: anemia, hemoconcentration, baseline immune status
• CMP/LFTs: renal and hepatic function to ensure safe metabolism and clearance
• Thyroid panel: TSH with free T4 (often adding free T3) because thyroid shifts SHBG, energy, and mood
• FSH (± LH): critical for ovarian status in peri/postmenopause and for interpretation while on contraceptives

Comprehensive metabolic-hormonal profile

• 25-OH vitamin D
• Vitamin B12
• HbA1c and fasting insulin
• CRP or hs-CRP
• DHEA-S
• Ferritin and iron studies
• Men: total and free testosterone, SHBG, estradiol (mass spectrometry if available), PSA
• Women: estradiol testing when it answers a specific question, acknowledging variability across the cycle

Rationale: The liver clears estrogens via phase I/II detoxification; thyroid shifts SHBG and peripheral conversion; iron status and vitamin D shape mitochondrial output; inflammation blunts receptor signaling. When these factors are optimized, patients tolerate hormones better and respond more predictably.

FSH, Estradiol, and Menopausal Physiology

When ovarian estrogen production declines, pituitary FSH rises via negative feedback—just as TSH rises with low thyroid hormone. In true postmenopause, FSH is elevated and relatively stable, while estradiol fluctuates and is a poor single-point diagnostic in many cycling women. Clinically:

• High FSH + low estrogen aligns with estrogen insufficiency postpartum and in menopause.
• Combined hormonal contraception suppresses gonadotropins; FSH can be misleadingly low.
• In a cycling woman, a single low estradiol level rarely justifies adding estrogen; ask if she is still cycling and correlate with symptoms.

For women on estradiol pellets, I often see FSH fall by roughly half after the first insertion (e.g., ~100 IU/L to ~40–50), with further stabilization toward ~20–40 over 2–4 insertions if symptoms and safety parameters align. The aim is to correct the deficiency without overshooting physiology.

Perimenopause Versus Postmenopause: Why Dosing Must Respect Physiology

Perimenopause is a neuroendocrine roller coaster. Ovaries still produce estrogen, but the fluctuations trigger hot flashes, sleep disturbance, anxiety, and migraines. Starting with postmenopausal-level doses may overshoot and worsen mastalgia, bloating, or bleeding. My approach:

• Start low-dose estradiol (e.g., a low-dose transdermal patch or a low-total-dose pellet) to set a floor that blunts dips without forcing peaks; titrate to symptom control and FSH trends.
• Add micronized progesterone at night for sleep and anxiety support and, in women with a uterus, endometrial protection.

In postmenopause, transdermal estradiol remains a top choice for safety—particularly in women at risk of clotting—while pellets can offer smoother day-to-day levels for those who prefer procedural convenience and steadier kinetics (NAMS, 2023).

---

Modulating Women’s Hormones-Video

---

Choosing Hormone Delivery: What I Use and Why

The “best” route depends on physiology, risks, and lifestyle fit.

Transdermal estradiol

• Avoids first-pass hepatic metabolism, reducing VTE risk relative to oral in many women (NAMS, 2023).
• Easy titration and reversibility.
• In women with a uterus, I pair with oral micronized progesterone (100–200 mg nightly) for endometrial protection and GABAergic sleep benefits.

Local vaginal estrogen or DHEA

• Excellent for genitourinary syndrome of menopause with minimal systemic absorption. For women with primarily local symptoms (dryness, dyspareunia, urinary urgency), local therapy alone may suffice.

Testosterone injections in men

• Effective but prone to peaks and troughs that can exacerbate aromatization to estradiol and 5?-reduction to DHT, triggering mood swings, acne, or erythrocytosis. I mitigate by splitting the weekly dose into twice-weekly subcutaneous injections to flatten spikes and improve tolerability (Bhasin et al., 2018; Pastuszak et al., 2015).

Testosterone microdosing in women

• I favor very low subcutaneous microdoses (e.g., small daily increments) to minimize androgenic side effects and stabilize mood and energy. Transdermal compounded testosterone can work for some but requires careful monitoring due to absorption variability. For women, I avoid bolus dosing.

Creams and site-specific delivery

• In women, carefully titrated labial testosterone or DHEA can enhance local sensory function due to the dense presence of androgen receptors.
• In men, scrotal testosterone cream can yield consistent absorption in select cases, but I monitor closely due to interpatient variability.

Pellet therapy

• Pellets provide sustained delivery and smoother pharmacokinetics, reducing peaks that drive surges in aromatase and 5?-reductase. Innovations such as ethylcellulose matrices slow diffusion and reduce early spikes, while judicious low-dose triamcinolone co-formulation can reduce local insertion-site inflammation without systemic steroid effects. In my practice, patients frequently report steadier sleep and libido with pellets and need fewer ancillary medications.

Why smoother kinetics matter

Testosterone is a prohormone. Large boluses elevate substrate for both aromatase (? estradiol) and 5?-reductase (? DHT). Flattening the curve reduces the risk of gynecomastia, fluid retention, and acne—especially in men—and reduces mood lability in both sexes.

Progesterone: Neurosteroid Powerhouse for Sleep and Safety

I favor micronized progesterone for its dual role in endometrial protection and sleep/anxiety modulation.

• Mechanism: Micronized progesterone metabolizes to allopregnanolone, a GABA-A receptor modulator that improves sleep continuity and reduces anxiety (Schüssler et al., 2011).
• Perimenopause: I typically start at 100 mg nightly; because cycle timing becomes erratic, steady nightly dosing often works better than luteal-only schedules.
• Postmenopause on estrogen: 200 mg nightly is common for endometrial protection, with dose/time adjustments for morning grogginess.
• Sublingual/vaginal routes: Without first-pass metabolism, lower doses can yield equivalent exposure; I generally prescribe about half the oral-equivalent when using these routes.
• I avoid relying on topical progesterone for endometrial protection because dermal absorption is inconsistent.

Optimizing Testosterone in Men: Dosing, Aromatization, and Safety

My objectives are to restore physiologic ranges, stabilize peaks and troughs, and minimize downstream adverse effects:

• Start with evidence-informed ranges and personalize: 100–200 mg/week of testosterone cypionate in adult men, adjusted based on symptoms and labs (Bhasin et al., 2018).
• Split doses and go subcutaneous: Two equal subcutaneous injections per week help flatten spikes, reducing the risk of aromatization and erythrocytosis (Pastuszak et al., 2015).
• Be conservative with aromatase inhibitors: I do not preemptively block estradiol. Estradiol supports endothelial and bone health in men; I adjust dose and frequency first and reserve AIs for persistent symptomatic hyperestrogenemia despite optimal dosing and lifestyle.

Monitoring strategy

• Baseline and serial labs: total and free testosterone (equilibrium dialysis or calculated), estradiol, CBC (hematocrit), CMP, fasting lipids, A1c, PSA (Bhasin et al., 2018).
• Trough timing: Draw just before the next scheduled dose after several injections to approximate steady state.
• Symptom scales: The Aging Male Symptoms (AMS) scale tracks sexual, somatic, and psychological domains over time (Heinemann, L.A.J., et al., 2003).

Fertility Preservation in Younger Men: Clomiphene First

For younger men with secondary hypogonadism who wish to preserve fertility, I often begin with clomiphene citrate (25–50 mg daily or every other day). Clomiphene stimulates pituitary LH/FSH secretion, thereby boosting endogenous testosterone and spermatogenesis without suppressing the axis (Krzastek et al., 2019). I start low, monitor symptoms, LH/FSH, total/free testosterone, estradiol, and semen parameters if fertility is a goal. Some men experience an early surge in libido; careful titration and sleep/autonomic balancing calm the edges. With age, LH signaling wanes; when clomiphene proves inadequate, I discuss trade-offs of exogenous testosterone.

Women and Testosterone: Microdosing, Outcomes, and Safety

Carefully selected women benefit from testosterone for hypoactive sexual desire disorder, cognitive slowing, low energy, and impaired muscle performance (Davis et al., 2019; NAMS, 2020). My method:

• Start very low and microdose subcutaneously to smooth pharmacokinetics and minimize androgenic effects.
• Pay attention to SHBG and free testosterone. High SHBG can suppress the free fraction; improving thyroid and insulin sensitivity may liberate biologically active hormone without excessively raising total testosterone.
• Monitor for virilizing side effects (acne, hirsutism, scalp hair changes, voice) and stop or reduce promptly if they occur.

Transitioning Between Modalities Without Valleys

When shifting delivery routes, preventing hormonal “valleys” avoids rebound irritability, headaches, and sleep disruption.

• From transdermal estradiol to pellets: I place pellets and continue the patch for 3–5 days, then discontinue as the pellet’s early release takes hold.
• From injections/gels to testosterone pellets: I maintain the prior modality for approximately two weeks post-insertion to bridge to steady-state pellet release.

Structured Follow-Up and Validated Symptom Scales

I pair symptom scales with labs to align physiology and lived experience:

• Women: Menopause Rating Scale (MRS) quantifies vasomotor, urogenital, and psychological symptoms (Heinemann, K. et al., 2003).
• Men: AMS scale tracks sexual, somatic, and psychological domains.
• Schedule: symptom check-ins at 4–6 weeks for early course-correcting; trough or steady-state labs at 8–12 weeks (especially with pellets); every 3–6 months thereafter for dose refinements and safety monitoring (hematocrit in men, blood pressure, lipids, body composition where feasible).

Complications and Side-Effect Mitigation

Most side effects are predictable and reversible:

• Local pellet-site irritation: antiseptic technique, proper trocar choice, and, when needed, low-dose triamcinolone co-formulation mitigate inflammation; antibiotics for true cellulitis; remove pellets only for unresponsive abscesses.
• Acne/oily skin: lower dose, favor smoother-release systems, support skin with topicals; reduce DHT conversion by addressing insulin resistance and inflammation.
• Hair shedding: check ferritin, thyroid, and androgens; replete deficiencies and adjust dose as needed.
• Erythrocytosis in men: monitor hematocrit; donate or reduce dose if >54% (Bhasin et al., 2018).
• Mood lability/aromatization: split injections, switch to smoother kinetics (pellets/transdermals), reduce visceral adiposity; avoid routine use.

The Integrative “Pump Method”: Layering for Clarity and Safety

To avoid signal noise, I layer interventions methodically:

1. Baseline screen and documentation: MRS or AMS; labs; vitals; body composition when available.

2. Foundation: BHRT, where indicated, including bioidentical estradiol, progesterone, or testosterone, individualized to symptoms and risks.

3. Thyroid and metabolic optimization: Normalize thyroid status and insulin sensitivity (consider GLP-1 receptor agonists based on metabolic needs) after hormones stabilize.

4. Gut and liver support: Address dysbiosis, constipation, and enterohepatic circulation; emphasize fiber and phytonutrients.

5. Targeted nutraceuticals: DHEA, omega-3s, magnesium glycinate; other botanicals, case-by-case, with quality controls.

6. Follow-up cadence: Reassess at 3–5 months for pellet kinetics and symptom evolution; consider a small “boost” dose if partially improved and safe.

When Antidepressants Aren’t Enough—and How I Taper

SSRIs can help with hot flashes and mood for some, but they do not replace estradiol or testosterone’s systemic roles in bone, muscle, and sexual function. When hormonal deficiency is the likely driver of mood and sleep issues, and after BHRT stabilizes, I collaborate to taper SSRIs:

• Option A: every other day for 2 weeks, then every third day for 2 weeks, then stop.
• Option B: halve the dose for 2 weeks, halve again if possible, then stop.
• If withdrawal or relapse occurs, return to the last stable dose for 7–10 days and resume a slower taper.

Clinical Observations from Health Coach Clinic

I regularly share case insights through Health Coach Clinic and my professional profile. A few representative patterns:

• A 52-year-old postmenopausal woman: Transdermal estradiol plus oral micronized progesterone improved vasomotor symptoms and sleep. After we optimized thoracic mobility, diaphragmatic mechanics, and vagal tone with chiropractic care, she stabilized further and eventually chose estradiol pellets for even steadier sleep and mood.
• A 34-year-old man with low drive and fatigue, desiring fertility: Clomiphene 25 mg every other day restored testosterone and improved semen parameters. Resistance training, scapular stability work, and sleep optimization supported energy and libido. An initial surge in libido settled with gentle titration and autonomic balancing.
• A 61-year-old man on injectable testosterone with acne and mood swings: Transitioned to testosterone pellets with an ethylcellulose matrix; aromatization decreased, acne cleared with topical care, and hematocrit stabilized with lower peaks.

Putting It All Together: My Stepwise Protocol

• Screen and baselines

• • Administer MRS or AMS.
  • Order labs: sex hormones, thyroid, CBC/CMP, metabolic and inflammatory markers as indicated.
  • Assess sleep apnea risk, cardiometabolic risk, and musculoskeletal status.

• Initiate conservative, individualized therapy.

• • Men: start 100–200 mg/week of cypionate, split into twice-weekly subcutaneous injections; titrate by symptoms and trough levels.
  • Women: begin very low-dose testosterone via subcutaneous microdosing when indicated; select low-dose estradiol in perimenopause, with progesterone for sleep and endometrial protection.
  • Postmenopause: prefer transdermal estradiol for safety with nightly micronized progesterone; consider pellets for steady-state convenience.

• Education and technique

• • Teach subcutaneous technique, site rotation, and post-injection dispersion to avoid nodules.
  • Provide written dose-splitting instructions and standardized trough lab timing.

• Integrate chiropractic and lifestyle.

• • Manual care and movement aligned with dosing rhythms; progressive resistance and posterior-chain emphasis.
  • Nutrition emphasizing protein adequacy and anti-inflammatory patterns; sleep hygiene and light routines to anchor circadian rhythms.

• Monitor and adjust

• • Recheck scales and trough/steady-state labs at 6–12 weeks; then every 3–6 months.
  • Adjust dosing frequency before considering aromatase inhibitors.
  • Monitor hematocrit, estradiol, PSA (men), and any postmenopausal bleeding (women).

Why This Approach Is Evidence-Based and Patient-Centered

• Transdermal estradiol offers safety advantages over oral in many women, particularly those with thrombotic risk (NAMS, 2023).
• Testosterone therapy is effective for hypoactive sexual desire disorder in women and symptomatic hypogonadism in men with careful monitoring (Bhasin et al., 2018; Davis et al., 2019; NAMS, 2020).
• Clomiphene preserves fertility while raising endogenous testosterone in younger men with secondary hypogonadism (Krzastek et al., 2019).
• Resistance training and metabolic health amplify hormone benefits and can lower dose requirements (Phillips & Winett, 2010).

My goal is not to chase perfect lab numbers but to restore physiologic function with the least risk and greatest quality-of-life gains. By coupling evidence-based endocrine care with integrative chiropractic strategies—restoring alignment, mobility, autonomic balance, and metabolic resilience—we transform insomnia into sleep, fatigue into vitality, and pain into performance.

References

• Bhasin, S., et al. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. academic.oup.com/jcem/article/103/5/1715/4939465
• Davis, S. R., et al. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Menopause. journals.lww.com/menopausejournal/Fulltext/2019/11000/Global_Consensus_Position_Statement_on_the_Use_of.12.aspx
• Haidar, A., et al. (2019). Subcutaneous testosterone: Pharmacokinetics and patient-reported outcomes. Contemporary Clinical Trials Communications. www.sciencedirect.com/science/article/abs/pii/S2050052118300856
• Heinemann, K., et al. (2003). Menopause Rating Scale: Psychometric validation. Archives of Gynecology and Obstetrics. link.springer.com/article/10.1007/s00404-000-0216-2
• Heinemann, L. A. J., et al. (2003). A new questionnaire to scale the symptoms of androgen deficiency in aging males (AMS). Aging Male. karger.com/and/article/4/5/221/110475/A-New-Questionnaire-to-Scale-the-Symptoms-of-Androgen
• International Society for the Study of Women’s Sexual Health. (2021). Clinical guideline for the use of systemic testosterone for HSDD in women. The Journal of Sexual Medicine. www.jsm.jsexmed.org/article/S1743-6095(21)00102-2/fulltext
• Khera, M., et al. (2011). The use of scrotal testosterone cream for hypogonadal men. The Journal of Sexual Medicine. www.jsm.jsexmed.org/
• Krzastek, S. C., et al. (2019). Clomiphene citrate and male hypogonadism: Efficacy and safety. The World Journal of Men’s Health. wjmh.org/DOIx.php?id=10.5534/wjmh.190007
• Maki, P. M., & Henderson, V. W. (2016). Hormone therapy, cognition, and dementia: The Women’s Health Initiative 15 years on. Climacteric. www.tandfonline.com/doi/full/10.1080/13697137.2016.1213451
• Morgentaler, A. (2011). Testosterone and prostate safety: Evidence synthesis. Prostate Cancer and Prostatic Diseases. www.nature.com/articles/pcan20119
• Morgentaler, A., et al. (2015). Testosterone therapy and cardiovascular risk: Advances and controversies. Mayo Clinic Proceedings. www.mayoclinicproceedings.org/article/S0025-6196(15)00130-1/fulltext
• North American Menopause Society. (2020). 2020 position statement on testosterone therapy for women. Menopause. journals.lww.com/menopausejournal
• North American Menopause Society. (2023). 2023 position statement on hormone therapy. Menopause. journals.lww.com/menopausejournal
• Pastuszak, A. W., et al. (2015). Hematocrit changes with testosterone therapy and mitigation strategies. Journal of Urology. www.auajournals.org/doi/full/10.1097/JU.0000000000000763
• Phillips, S. M., & Winett, R. A. (2010). Uncomplicated resistance training and health-related outcomes. Current Sports Medicine Reports. journals.lww.com/acsm-csmr
• Ramasamy, R., et al. (2016). Aromatase inhibitors in men on testosterone: Risks and benefits. European Urology. www.sciencedirect.com/science/article/abs/pii/S0302283815016847
• Sarri, G., et al. (2020). Effects of menopausal hormone therapy on vasomotor symptoms and quality of life. BMJ. www.bmj.com/content/371/bmj.m3853
• Schüssler, P., et al. (2011). Micronized progesterone and sleep: Mechanisms and clinical evidence. Pharmacopsychiatry. www.sciencedirect.com/science/article/abs/pii/S0378512212005035
• Snyder, P. J., et al. (2016). Cardiovascular safety of testosterone replacement therapy in men. New England Journal of Medicine. www.nejm.org/doi/full/10.1056/NEJMoa1506119
• Traish, A. M., et al. (2011). Testosterone and its metabolites: Basic physiology and clinical implications. The Journal of Sexual Medicine. www.jsm.jsexmed.org/

About my clinical approach

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My work at Health Coach Clinic integrates chiropractic care, functional medicine, and nurse practitioner-led endocrinology to deliver comprehensive, evidence-based plans for hormone health and musculoskeletal resilience. Learn more at healthcoach.clinic/ and www.linkedin.com/in/dralexjimenez/.

SEO tags: hormone optimization, estradiol therapy, testosterone therapy, progesterone sleep, hormone pellets, ethylcellulose pellets, triamcinolone pellets, clomiphene citrate, aromatase management, DHT control, subcutaneous testosterone, transdermal estradiol patch, vaginal estrogen, DHEA vaginal, menopause FSH, perimenopause treatment, AMS scale, Menopause Rating Scale, integrative chiropractic, vagal tone, resistance training, functional medicine hormones, SSRI taper, cardiometabolic health